Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,687 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety and tolerability of denufosol tetrasodium inhalation solution, a novel P2Y2 receptor agonist: results of a phase 1/phase 2 multicenter study in mild to moderate cystic fibrosis.
Deterding R, Retsch-Bogart G, Milgram L, Gibson R, Daines C, Zeitlin PL, Milla C, Marshall B, Lavange L, Engels J, Mathews D, Gorden J, Schaberg A, Williams J, Ramsey B; Cystic Fibrosis Foundation Therapeutics Development Network. Deterding R, et al. Among authors: marshall b. Pediatr Pulmonol. 2005 Apr;39(4):339-48. doi: 10.1002/ppul.20192. Pediatr Pulmonol. 2005. PMID: 15704203 Clinical Trial.
Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group.
Ramsey BW, Pepe MS, Quan JM, Otto KL, Montgomery AB, Williams-Warren J, Vasiljev-K M, Borowitz D, Bowman CM, Marshall BC, Marshall S, Smith AL. Ramsey BW, et al. Among authors: marshall bc, marshall s. N Engl J Med. 1999 Jan 7;340(1):23-30. doi: 10.1056/NEJM199901073400104. N Engl J Med. 1999. PMID: 9878641 Free article. Clinical Trial.
Probability of treatment following acute decline in lung function in children with cystic fibrosis is related to baseline pulmonary function.
Morgan WJ, Wagener JS, Yegin A, Pasta DJ, Millar SJ, Konstan MW; Scientific Advisory Group, investigators; coordinators of the Epidemiologic Study of Cystic Fibrosis. Morgan WJ, et al. J Pediatr. 2013 Oct;163(4):1152-7.e2. doi: 10.1016/j.jpeds.2013.05.013. Epub 2013 Jun 27. J Pediatr. 2013. PMID: 23810128 Free PMC article.
Standard care versus protocol based therapy for new onset Pseudomonas aeruginosa in cystic fibrosis.
Mayer-Hamblett N, Rosenfeld M, Treggiari MM, Konstan MW, Retsch-Bogart G, Morgan W, Wagener J, Gibson RL, Khan U, Emerson J, Thompson V, Elkin EP, Ramsey BW; EPIC; ESCF Investigators. Mayer-Hamblett N, et al. Pediatr Pulmonol. 2013 Oct;48(10):943-53. doi: 10.1002/ppul.22693. Epub 2013 Jul 2. Pediatr Pulmonol. 2013. PMID: 23818295 Free PMC article. Clinical Trial.
Socioeconomic status and the likelihood of antibiotic treatment for signs and symptoms of pulmonary exacerbation in children with cystic fibrosis.
Schechter MS, McColley SA, Regelmann W, Millar SJ, Pasta DJ, Wagener JS, Konstan MW, Morgan WJ; Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis. Schechter MS, et al. J Pediatr. 2011 Nov;159(5):819-824.e1. doi: 10.1016/j.jpeds.2011.05.005. Epub 2011 Jun 25. J Pediatr. 2011. PMID: 21705017 Free PMC article.
Pulmonary exacerbations in CF patients with early lung disease.
Anstead M, Saiman L, Mayer-Hamblett N, Lands LC, Kloster M, Goss CH, Rose L, Burns JL, Marshall B, Ratjen F. Anstead M, et al. Among authors: marshall b. J Cyst Fibros. 2014 Jan;13(1):74-9. doi: 10.1016/j.jcf.2013.07.006. Epub 2013 Sep 10. J Cyst Fibros. 2014. PMID: 24029220 Free article. Clinical Trial.
1,687 results